{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Pharmacodynamics: tumor blood flow in patients with AML and FLT3-ITD mutation using dynamic contrast enhanced MRI (DEMRI) (Part C).","groups":[{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG000","title":"Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2"}],"populationDescription":"This data were not and will never be collected","reportingStatus":"POSTED","timeFrame":"1 week prior to enrollment, then every 28 days","title":"Pharmacodynamics (PD) Blood Flow Part C","type":"SECONDARY"}